SMARCA2 Inhibitor LY4050784

**Semantic type:** Pharmacologic Substance

**Definition:** An orally bioavailable allosteric inhibitor of SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 2 (SMARCA2; BRM), with potential antineoplastic activity. Upon oral administration, SMARCA2 inhibitor LY4050784 targets, binds to and inhibits the activity of SMARCA2. This may lead to the inhibition of the SWI/SNF (BRG1/BRM-associated factor; BAF) chromatin remodeling complex, disrupt chromatin remodeling and gene expression, and result in the downregulation of oncogenic pathways and the inhibition of tumor cell proliferation in SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 4 (SMARCA4; BRG1)-deleted cancers. SMARCA2 and SMARCA4 are the primary ATPase components and mutually exclusive core catalytic subunits of the SWI/SNF chromatin remodeling complex, an important regulator of transcriptional programs and gene expression. SMARCA4 expression is absent in certain cancer cells, and these SMARCA4-deleted cancer cells depend on SMARCA2 for survival.

**Synonyms:** - BRM Inhibitor FHD-909 - BRM Inhibitor LY4050784 - FHD 909 - FHD-909 - FHD909 - LY 4050784 - LY-4050784 - LY4050784 - SMARCA2 Inhibitor FHD-909